Nurix Therapeutics, Inc.

Nurix Therapeutics announced updated Phase 1a/1b clinical data for its novel Bruton's tyrosine kinase (BTK) degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), to be presented at EHA2026. The data demonstrated a favorable safety profile and durable responses, with an objective response rate (ORR) of 83.0% and a median progression-free survival (PFS) of 22.1 months in heavily pretreated patients. In earlier-line cohorts, ORR reached 92.9% in BTKi-treated, BCL2i-naïve patients and 84.2% in BTKi-naïve patients.

Nurix Therapeutics, Inc. has entered into a global License and Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, Roche) for bexobrutideg (NX-5948), an investigational BTK degrader. Under the agreement, Nurix grants Roche an exclusive worldwide license, and Roche will make an upfront payment of $700 million. Nurix is eligible for up to $2.3 billion in total payments, including milestones. The companies will co-develop and co-commercialize bexobrutideg in the U.S., sharing profits and losses equally, while Roche will handle ex-U.S. development and commercialization, with Nurix receiving tiered royalties. Development costs will be shared 40% by Nurix and 60% by Roche.

Nurix Therapeutics announced a global collaboration with Roche to develop and commercialize bexobrutideg, a potential best-in-class oral degrader of Bruton's tyrosine kinase (BTK). Nurix will receive an upfront cash payment of $700 million and is eligible for up to $2.3 billion in potential development, regulatory, and sales milestones. The partnership includes a comprehensive clinical development plan across malignant hematology, immunology, and neurology, with shared profits and losses in the U.S. and royalties for Nurix on ex-U.S. sales.

Nurix Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where a quorum was established with 80.98% of voting power present. Stockholders elected three Class III directors, Arthur T. Sands, Roger Dansey, and Paul M. Silva, each to serve a three-year term. Additionally, the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026 was ratified, and the compensation of the company's named executive officers was approved on a non-binding advisory basis.

Nurix Therapeutics, Inc. announced that its President and CEO, Arthur T. Sands, M.D., Ph.D., will participate in fireside chats at two upcoming investor conferences. He is scheduled to present at the RBC Global Healthcare Conference on May 20, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026. Both presentations will be webcast live and archived for 30 days on the company's investor relations website.

Nurix Therapeutics announced new positive preclinical data from its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. The presentations highlighted continued progress across programs targeting pan-mutant BRAF, CBL-B, and Aurora Kinase A (AURKA), reinforcing the potential of degraders to overcome limitations of traditional inhibitors. Specifically, the pan-mutant BRAF degrader NRX-0305 demonstrated potent antitumor activity and significantly extended survival by 142% in a resistant melanoma brain metastasis model, suggesting a promising new therapeutic modality.

Nurix Therapeutics reported its first quarter 2026 financial results, highlighting significant progress in its clinical pipeline, particularly for bexobrutideg. The company is actively enrolling patients in the pivotal Phase 2 DAYBreak CLL-201 study, aiming for Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL), and plans to initiate a confirmatory Phase 3 trial by mid-2026. Additionally, Nurix is expanding bexobrutideg's potential into inflammatory and autoimmune indications with a new tablet formulation, targeting a 2026 IND submission. With a strong balance sheet of $540.7 million, Nurix is well-positioned to advance its registrational programs and broader pipeline, including partnered degraders for IRAK4 and STAT6.